Our Partners

RSS Investor Relations and News

  • MYOS RENS Technology Launches Advanced Veterinary Supplement Product For Dogs, Powered By Fortetropin® June 06, 2018
    ENTERS INTO THE $500 MILLION U.S. PET SUPPLEMENTS MARKET PRODUCT DEVELOPED TO SUPPORT MUSCLE HEALTH IN DOGS CEDAR KNOLLS, N.J., June 6, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived [...]
    MYOS RENS Technology Reports First Quarter Financial Results May 09, 2018
    Provides Update on Clinical Studies Programs Conference Call to be Held Tomorrow at 11am ET CEDAR KNOLLS, N.J., May 9, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or the "Company") (NASDAQ: MYOS), a bionutrition company and owner of Fortetropin®, the  product that helps build lean muscle in conjunction with resistance training, [...]
    Learn More ›
  • MYOS RENS Technology Q1 2018 Financial Results Conference Call

    Digital replay is available through July 31, 2018. The replay may be accessed by dialing 877-660-6853 from the U.S. or 201-612-7415 for international callers, Conference ID# 13679724.


    Webcast

    MicroCap Conference

    Essex House - New York City

Stock Snapshot

MYOS Symbol
NASDAQ Market
Market Cap
Price
Change
Volume